Publication Name	World Journal of Clinical Oncology
Manuscript ID	108585
Country	Japan

Received	2025-04-18 05:16
Peer-Review Started	2025-04-18 05:16
To Make the First Decision
Return for Revision	2025-05-15 00:34
Revised	2025-05-22 13:41
Second Decision	2025-08-04 02:52
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-08-04 10:50
Articles in Press	2025-08-04 10:50
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-09-01 06:01
Publish the Manuscript Online	2025-09-23 06:48

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Minireviews
Article Title	Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies
Manuscript Source	Invited Manuscript
All Author List	Hiroki Goto, Mariko Takano, Yoshioki Shiraishi and Sudjit Luanpitpong
Funding Agency and Grant Number
Corresponding Author	Hiroki Goto, MD, PhD, Division of Radioisotope and Tumor Pathobiology, Institute of Resource Development and Analysis, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan. hgoto20@kumamoto-u.ac.jp
Key Words	Immuno-positron emission tomography; Hematologic malignancies; Lymphoma; Myeloma; Leukemia; Antibody; Single-domain antibody; Precision medicine; Theranostics
Core Tip	Fluorine-18 (18F)-fluorodeoxyglucose (FDG)-PET is commonly used to detect residual tumor cells and evaluate treatment responses in hematologic malignancies. However, as FDG uptake reflects glucose metabolism, it does not accurately indicate the presence of tumor cells expressing specific antigens. Recent studies have introduced immuno-PET, which labels antibodies or other immune-targeting molecules with positron-emitting radionuclides, as a promising alternative for visualizing tumor distribution and assessing therapeutic responses. This technique provides a specific imaging approach. In this minireview, we highlight recent progress in immuno-PET and discuss its future clinical applications in the management of hematologic malignancies.
Publish Date	2025-09-23 06:48
Citation	<p>Goto H, Takano M, Shiraishi Y, Luanpitpong S. Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies. <i>World J Clin Oncol</i> 2025; 16(9): 108585</p>
URL	https://www.wjgnet.com/2218-4333/full/v16/i9/108585.htm
DOI	https://dx.doi.org/10.5306/wjco.v16.i9.108585

Full Article (PDF)	WJCO-16-108585-with-cover.pdf
Manuscript File	108585_Auto_Edited_015138.docx
Answering Reviewers	108585-answering-reviewers.pdf
Audio Core Tip	108585-audio.m4a
Conflict-of-Interest Disclosure Form	108585-conflict-of-interest-statement.pdf
Copyright License Agreement	108585-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	108585-non-native-speakers.pdf
Supplementary Material	108585-supplementary-material.pdf
Peer-review Report	108585-peer-reviews.pdf
Scientific Misconduct Check	108585-scientific-misconduct-check.png
Scientific Editor Work List	108585-scientific-editor-work-list.pdf
CrossCheck Report	108585-crosscheck-report.pdf